Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital. 

Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).

Moderna Inc. said on April 28 the U.S. government had agreed to increase the contract for the company’s Covid-19 vaccine by $236 million to roughly $1.25 billion, to include additional costs related to the shot’s studies.

Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China

Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.

Oncology startup Volastra Therapeutics inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced the New York-based company’s seed funding round was extended from $12 million to $44 million.

Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.

Takeda Pharmaceutical is advancing the Japanese pharma giant’s immune-oncology portfolio through the acquisition of the immunotherapy pioneer Maverick Therapeutics.

Shares of Ovid Therapeutics soared in trading after the company announced pharma giant Takeda signed a licensing agreement valued at $856 million to secure global rights to the investigational medicine soticlestat for the treatment of two forms of rare epilepsy.

Shares of Pandion Therapeutics soared more than 131 percent in trading after pharma giant Merck announced the acquisition of the autoimmune-focused company for up to $1.85 billion.